# A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants

> **NCT04893551** · PHASE1 · TERMINATED · sponsor: **BerGenBio ASA** · enrollment: 16 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **BIOLOGICAL:** Tilvestamab

## Key facts

- **NCT ID:** NCT04893551
- **Lead sponsor:** BerGenBio ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-25
- **Primary completion:** 2022-06-27
- **Final completion:** 2022-06-27
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** After completion of all planned dose levels in the dose escalation phase, the sponsor decision was not to continue with expanding the cohorts of any of the dose levels, using the existing study design.
- **Last updated:** 2023-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04893551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04893551, "A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04893551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*